MAPT and Alzheimer disease: These opposite tau effects of TEMT in CSF from AD subjects are exactly what would be expected based on our recent finding that the AD brain homogenates exposed to an identical TEMT treatment protocol over seven days responded with (1) a decrease in p-tau levels (i.e., a reversal of abnormal tau hyper-phosphorylation) and (2) an increase in t-tau levels (which is almost exclusively monomeric) [ref.-unpublished observations].